Is DARE or DMRA more undervalued in 2026?

CirclFi compares Dare Bioscience, Inc. (DARE) and Damora Therapeutics, Inc. (DMRA) using 13 institutional-grade valuation models. DARE has a Quality of Company score of 4.4/10 while DMRA scores 4.8/10.

Which is a better buy — DARE or DMRA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do DARE and DMRA valuations compare?

DARE at $2.28 and DMRA at $24.84 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

DARE vs DMRA Valuation Comparison 2026 — Intrinsic Value Analysis

DARE

Biotechnology

Dare Bioscience, Inc.

Quality

4.4

out of 10

Value Trap

LOW

Price

$2.28

Last close

Models

9/13

Active

DMRA

Biotechnology

Damora Therapeutics, Inc.

Quality

4.8

out of 10

Value Trap

SAFE

Price

$24.84

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	DARE Fair Value	DARE Upside	DMRA Fair Value	DMRA Upside
Bayesian DCF	Intrinsic	$1.22	-46.5%	$7.40	-70.2%
Earnings Power Value	Intrinsic	—	—	$6.07	-75.0%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$2.81	+23.3%	$9.09	-63.4%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for DARE vs DMRA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

DARE vs DMRA — Which Stock Is More Undervalued?

DMRA scores higher with a 4.8/10 quality rating vs DARE's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Dare Bioscience, Inc. (DARE) and Damora Therapeutics, Inc. (DMRA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

DARE currently trades at $2.28 with a QOC of 4.4/10, while DMRA trades at $24.84 with a QOC of 4.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).